Status:
COMPLETED
Interplay Between Immune and Metabolic Programs in Myelodysplastic Syndromes
Lead Sponsor:
University Hospital, Toulouse
Conditions:
Myelodysplastic Syndromes
Eligibility:
All Genders
18-99 years
Brief Summary
Myelodysplastic syndromes (MDS) are a pre-leukemic condition with an extremely poor prognosis despite current treatments that justify new therapeutic approaches. Various studies have described the pot...
Detailed Description
Myelodysplastic syndromes (MDS) are a pre-leukemic condition with an extremely poor prognosis despite current treatments. It is the most frequent haematological disorder after the age of 65. Different...
Eligibility Criteria
Inclusion
- Patients:
- Patient over 18 years of age with a myelodysplastic syndrome (WHO 2016 classification) of low risk (LR=IPSS-R\<4.5) or high risk (HR=IPSS-R\>4.5);
- Patient naïve to specific treatment of MDS;
- Patient who expressed no opposition to participating in the study. ;
- Patient affiliated with the social security system.
- Control:
- over 18 years of age,
- Sample from blood donation (regardless of age) Or Patient \>60 years old, see at the geriatrics platform of the hospital la Grave (CHU of Toulouse),
- having expressed his non opposition to participate in the study
Exclusion
- Patients:
- Myeloid disease other than MDS (including chronic myelomonocytic leukemia and MDS/SMP) ;
- Ongoing treatments for MDS (excluding erythropoietin, granulocyte colony-stimulating factor and transfusions) ;
- Medical conditions that may interfere with immune system testing: active cancer, active autoimmune disease, inflammatory conditions, immunosuppressive therapy. ; \* Pregnant or breastfeeding women ; Patient's refusal ;
- Person benefiting from a system of protection for adults (including guardianship, curators and safeguarding of justice)
- Control:
- Medical conditions that may interfere with immune system testing: active cancer, active autoimmune disease, inflammatory conditions, immunosuppressive therapy. ; \* Pregnant or breastfeeding women ;
- Patient's refusal ;
- Person benefiting from a system of protection for adults (including guardianship, curators and safeguarding of justice)
Key Trial Info
Start Date :
February 23 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2024
Estimated Enrollment :
137 Patients enrolled
Trial Details
Trial ID
NCT04803721
Start Date
February 23 2021
End Date
January 1 2024
Last Update
February 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
IUCT-Oncopole University Hospital
Toulouse, France, 31500